公开(公告)号：US11634488B2

公开(公告)日：2023-04-25

申请号：US16630351

申请日：2018-07-10

Applicant: INTERNATIONAL—DRUG—DEVELOPMENT—BIOTECH

Inventor： Claudine Vermot-Desroches ,  Chanthy Kong-Flohr ,  Marc Godinat ,  Bruno Cavallini

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti-CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL).